News archives


OCTOBER - DECEMBER 17

JULY - SEPTEMBER 17

APRIL - JUNE 17

JANUARY - MARCH 17

OCTOBER - DECEMBER 16

JULY - SEPTEMBER 16

APRIL - JUNE 16

JANUARY - MARCH 16

OCTOBER - DECEMBER 15

JULY - SEPTEMBER 15

APRIL - JUNE 15

JANUARY - MARCH 15

OCTOBER - DECEMBER 14

JULY - SEPTEMBER 14

APRIL - JUNE 14

JANUARY - MARCH 14

OCTOBER - DECEMBER 13

JULY - SEPTEMBER 13

APRIL - JUNE 13

JANUARY - MARCH 13

OCTOBER - DECEMBER 12

JULY - SEPTEMBER 12

APRIL - JUNE 12

JANUARY - MARCH 12

OCTOBER - DECEMBER 11

JULY - SEPTEMBER 11

APRIL - JUNE 11

JANUARY - MARCH 11

OCTOBER - DECEMBER 10

JULY - SEPTEMBER 10

APRIL - JUNE 10

JANUARY - MARCH 10

OCTOBER - DECEMBER 09

JULY - SEPTEMBER 09

APRIL - JUNE 09

JANUARY - MARCH 09

OCTOBER - DECEMBER 08

JULY - SEPTEMBER 08

APRIL - JUNE 08

JANUARY - MARCH 08

OCTOBER - DECEMBER 07

JULY - SEPTEMBER 07

APRIL - JUNE 07

JANUARY - MARCH 07

 
  current news   Press   selected story    
     
  1 July 2015  
 
Microstructured Dextran Hydrogels for Burst-Free Sustained Release of PEGylated Protein Drugs
 
 




Authors
Ki Hyun Baea, Fan Leea, Keming Xua, Choong Tat Kengb, Sue Yee Tanb, Yee Joo Tanb,c, Qingfeng Chenb,c,d,*, and Motoichi Kurisawaa,*

a Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, Singapore 138669.
b Institute of Molecular and Cell Biology, 61 Biopolis Drive, The Proteos, Singapore 138673.
c Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore,   Singapore 119228.
d Interdisciplinary Research Group in Infectious Diseases, Singapore-Massachusetts Institute of   Technology Alliance for Research and Technology, Singapore 138602.

To whom correspondence should be addressed.
   Email: qchen@imcb.a-star.edu.sg, mkurisawa@ibn.a-star.edu.sg

Published in Biomaterials in September 2015, Volume 63, Pages 146–157.

Abstract

There is a lack of animal models to test the safety and efficacy of drugs which specifically target human. We developed humanized mice to directly conduct pharmacokinetics and biocompatibility studies of human PEG-IFN-α2a in vivo. These mice were established by adoptive transfer of human CD34+ fetal liver cells into NOD-scid Il2rg-/- mice. Such humanized mice with a functional human immune system allow assessment of the efficacy and safety of human therapeutic proteins in a physiologically relevant manner without immunogenicity problems. Following subcutaneous (s.c.) injection of PEG-IFN-α2a solution, its plasma concentration reached a peak within 1 day and declined to undetectable levels after 2 weeks. The mice implanted with Dex-Tyr hydrogels showed a similar trend, suggesting that PEG-IFN-α2a loaded in these hydrogels was quickly diffused out and cleared from the bloodstream. In contrast, a one-time administration of Dex-Tyr/PEG hydrogels resulted in prolonged circulation of PEG-IFN-α2a for 7 weeks. Furthermore, these hydrogels significantly increased the plasma half-life of PEG-IFN-α2a from 1.5 ± 0.2 to 15.6 ± 1.4 days. Therefore, these results demonstrated that Dex-Tyr/PEG hydrogels enabled continuous release of the encapsulated PEG-IFN-α2a in vivo. The PEG-IFN-α2a-loaded Dex-Tyr/PEG hydrogels also show therapeutic effects in a humanized mouse model of hepatitis C.

Figure:

Figure legend: Pharmacokinetics and therapeutic effect of PEG-IFN-α2a in humanized mice. (A) Plasma concentration-time profiles following subcutaneous administration of PEG-IFN-α2a solution, Dex-Tyr hydrogels or Dex-Tyr/PEG hydrogels with 3 μm domains. (B) Plasma half-life of PEG-IFN-α2a determined from pharmacokinetics analysis. Results are presented as mean ± SD (n = 3). *P < 0.005 vs. PEG-IFN-α2a alone or Dex-Tyr hydrogels. (C and D) H&E (C) and Sirius Red (D) stained liver sections from uninfected humanized mice and HCV-infected humanized mice treated with PBS, PEG-IFN-α2a (a one-time, monthly or weekly subcutaneous injection) or Dex-Tyr/PEG hydrogels (a one-time subcutaneous implantation). Scale bars, 100 μm. (E) Serum levels of ALT in humanized mice with treatments. Results are presented as mean ± SEM (n = 5). Significance levels were set at: *P < 0.05 and **P < 0.005.


For more information on Qingfeng CHEN's laboratory, please click here.